Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil.
Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil.
Anaerobe. 2019 Oct;59:163-166. doi: 10.1016/j.anaerobe.2019.07.002. Epub 2019 Jul 9.
Clostridium perfringens type A is the causative agent of gas gangrene and gastroenteric ("yellow lamb disease") disease in ruminants, with C. perfringens alpha toxin (CPA) being the main virulence factor in the pathogenesis of these illnesses. In the present study, we have developed recombinant Escherichia coli bacteria expressing rCPA and used it to vaccinate rabbits and sheep. Doses of up to 200 μg of rCPA used for inoculation, induced 13.82 IU.mL of neutralizing antitoxin in rabbits, which is three times higher than that recommended by the USDA (4 IU.mL). In sheep, recombinant bacteria induced antitoxin titers of 4 IU.mL, 56 days after the first dose. rCPA which was expressed, mainly, in inclusion bodies, was not found to influence the immunogenicity of the vaccine. The recombinant Escherichia coli bacterin, produced simply and safely, is capable of affording protection against diseases caused by C. perfringens CPA. The current findings represent a novel production method for CPA vaccines potentially applicable to veterinary medicine.
A 型产气荚膜梭菌是引起反刍动物气性坏疽和胃肠型(“黄羔病”)疾病的病原体,α 毒素(CPA)是这些疾病发病机制中的主要毒力因子。在本研究中,我们开发了表达 rCPA 的重组大肠杆菌,并将其用于接种兔子和绵羊。高达 200µg 的 rCPA 用于接种,可诱导兔子产生 13.82 IU.mL 的中和抗毒素,是美国农业部推荐量(4 IU.mL)的三倍。在绵羊中,首次剂量后 56 天,重组细菌诱导的抗毒素滴度为 4 IU.mL。主要以包涵体形式表达的 rCPA 未发现影响疫苗的免疫原性。该重组大肠杆菌菌苗简单、安全地生产,能够提供针对产气荚膜梭菌 CPA 引起的疾病的保护。目前的研究结果代表了一种潜在适用于兽医领域的 CPA 疫苗的新型生产方法。